Additionally, the 36-month beta value for CATX is 1.16. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CATX is 48.92M and currently, short sellers hold a 20.26% ratio of that float. The average trading volume of CATX on December 27, 2024 was 1.54M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CATX) stock’s latest price update
Perspective Therapeutics Inc (AMEX: CATX)’s stock price has gone rise by 1.23 in comparison to its previous close of 3.25, however, the company has experienced a 10.77% increase in its stock price over the last five trading days. seekingalpha.com reported 2024-12-23 that Perspective Therapeutics’ radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company’s theranostics approach that delivers radiation directly to tumors. This can potentially minimize healthy tissue damage, and it has already had promising early results in neuroendocrine tumors. Currently, CATX’s main candidates are VMT01 for melanoma and VMT-α-NET for neuroendocrine tumors. They’re both in Phase 1/2 trials, and VMT01 has Fast Track Designation.
CATX’s Market Performance
Perspective Therapeutics Inc (CATX) has seen a 10.77% rise in stock performance for the week, with a -10.84% decline in the past month and a -73.16% plunge in the past quarter. The volatility ratio for the week is 9.59%, and the volatility levels for the past 30 days are at 9.75% for CATX. The simple moving average for the last 20 days is -6.69% for CATX’s stock, with a simple moving average of -72.76% for the last 200 days.
Analysts’ Opinion of CATX
Many brokerage firms have already submitted their reports for CATX stocks, with BofA Securities repeating the rating for CATX by listing it as a “Neutral.” The predicted price for CATX in the upcoming period, according to BofA Securities is $5 based on the research report published on November 25, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see CATX reach a price target of $20. The rating they have provided for CATX stocks is “Buy” according to the report published on October 24th, 2024.
Wedbush gave a rating of “Outperform” to CATX, setting the target price at $25 in the report published on October 01st of the current year.
CATX Trading at -55.60% from the 50-Day Moving Average
After a stumble in the market that brought CATX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.73% of loss for the given period.
Volatility was left at 9.75%, however, over the last 30 days, the volatility rate increased by 9.59%, as shares sank -25.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -73.81% lower at present.
During the last 5 trading sessions, CATX rose by +10.77%, which changed the moving average for the period of 200-days by -71.39% in comparison to the 20-day moving average, which settled at $3.53. In addition, Perspective Therapeutics Inc saw -18.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CATX starting from HENSON HEIDI, who purchase 25,975 shares at the price of $3.85 back on Dec 04 ’24. After this action, HENSON HEIDI now owns 25,975 shares of Perspective Therapeutics Inc, valued at $100,004 using the latest closing price.
Spoor Johan M., the CEO of Perspective Therapeutics Inc, purchase 8,000 shares at $3.77 during a trade that took place back on Dec 04 ’24, which means that Spoor Johan M. is holding 36,257 shares at $30,132 based on the most recent closing price.
Stock Fundamentals for CATX
Current profitability levels for the company are sitting at:
- -159.37 for the present operating margin
- 1.0 for the gross margin
The net margin for Perspective Therapeutics Inc stands at -189.27. The total capital return value is set at -0.15. Equity return is now at value -29.53, with -27.07 for asset returns.
Based on Perspective Therapeutics Inc (CATX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -370.4.
Currently, EBITDA for the company is -39.96 million with net debt to EBITDA at 4.93. When we switch over and look at the enterprise to sales, we see a ratio of 0.56. The receivables turnover for the company is 1.55for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.60.
Conclusion
In conclusion, Perspective Therapeutics Inc (CATX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
